PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorKing's College London

About this trial

Some people experience chest pain and shortness of breath, but when they have tests, no blockages are found in their main heart arteries. The most common cause of symptoms is related to abnormalities in the small blood vessels, also known as 'small vessel angina' or Coronary Microvascular Dysfunction (CMD). Currently, the diagnosis of CMD requires additional measurements of blood flow in the heart vessel during a minimally invasive procedure known as a coronary angiogram.

CMD affects many people and can lead to repeated hospital visits and a lower quality of life, and diagnosing the condition leads to better patient outcomes. However, there are still no widely available, proven treatments for this condition and therefore several patients remain symptomatic.

This study aims to find better ways to treat CMD, especially by understanding how the heart uses energy and how this might relate to symptoms.

Eligibility criteria

Qualifiers

Angina with non-obstructive coronary arteries

Disqualifiers

Significant epicardial coronary stenoses

Inability to carry out bike exercise

Contra-indication to adenosine administration

Insulin usage with frequent hypoglycaemic episodes

Trial design

Treatments tested in this trial

  • Empagliflozin 10mg OD

Treatment groups

100 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

King's College London

Lead sponsor

Guy's and St Thomas' NHS Foundation Trust

Collaborator